Dublin Automation Expansion Could Be A Game Changer For West Pharmaceutical Services' Contract Platform (WST)
West Pharmaceutical Services (WST) has expanded its Dublin facility with advanced automation to bolster its contract services for high-volume injectable therapies like diabetes and obesity treatments. This move aims to solidify its position as an integrated partner for pharmaceutical companies, supporting its investment thesis focusing on high-value components and services. The expansion, alongside the sale of its SmartDose manufacturing rights, signals a shift towards drug handling-centric contract services, which could impact its margins and capital intensity.
Q3 2024 West Pharmaceutical Services Inc Earnings Call Transcript
West Pharmaceutical Services Inc (WST) reported solid financial results for Q3 2024, with revenues and adjusted EPS at the high end of expectations, leading to an increased full-year adjusted EPS guidance. The company, a leader in biologics within injectables, is investing in capacity expansion and seeing growth in GLP-1s and wearable self-injection devices. Despite these positive trends, WST faced challenges including a low single-digit decline in organic sales, decreased operating profit and diluted EPS compared to the prior year, and ongoing destocking with some generic customers which is anticipated to continue into 2025.
A Look At West Pharmaceutical Services (WST) Valuation After New Dublin Expansion For Injectable Treatments
West Pharmaceutical Services (WST) has expanded its Dublin site to support high-volume injectable treatments for diabetes and obesity. Despite recent share price pressure, analysts suggest the stock is undervalued, with a fair value of $338.57 against a current trading price of US$254.80. However, its high P/E ratio compared to the industry indicates a potential valuation risk if market sentiment shifts.
West Pharmaceutical Services, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics
West Pharmaceutical Services, Inc. has seen a stock price adjustment and a revision in its evaluation amid changing market dynamics. The company's stock, currently priced at $243.35, has shown mixed performance over the past year compared to the S&P 500, with significant volatility. While technical indicators suggest bearish sentiment in some short-term views, a ten-year return of 272.38% indicates a long-term growth trajectory warranting continued observation by stakeholders.
ResMed Inc. (RMD) stock price, news, quote and history
This article provides comprehensive financial data, news, and historical information for ResMed Inc. (RMD). It includes real-time stock quotes, key statistics, performance over various periods, an overview of the company's operations in medical devices and cloud-based software, and analyst insights. The report also lists financial highlights, profitability metrics, and allows for comparison with similar companies in the Medical Instruments & Supplies industry.
West Pharmaceutical Services, Inc. (NYSE:WST) Given Consensus Rating of "Buy" by Analysts
West Pharmaceutical Services (NYSE:WST) has received a consensus "Buy" rating from analysts, with an average 12-month price target of $314.56. The company recently reported strong Q4 earnings, beating estimates with $2.04 EPS and $805 million in revenue, and issued optimistic guidance for FY2026. Additionally, West Pharmaceutical Services announced a $1 billion share repurchase program and a quarterly dividend of $0.22 per share.
Resmed to post quarterly results after market close on April 30
ResMed (NYSE: RMD) announced it will release its third-quarter fiscal year 2026 financial and operational results on Thursday, April 30, 2026, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results, which will be accessible via its investor relations website, with replays also available. The announcement emphasizes the company's consistent practice of providing transparency regarding its financial disclosures.
[Form 4] WEST PHARMACEUTICAL SERVICES INC Insider Trading Activity
WEST PHARMACEUTICAL SERVICES INC director Janet Brutschea Haugen reported acquiring 52 Phantom Stock Units, valued at $250.64 each, increasing her total to approximately 260.494 units. These units will convert to shares upon her termination of service. The filing also notes her direct holding of 1,321.258 shares of common stock and 1,071 restricted stock units and dividend equivalents that vest at the next annual shareholder meeting.
WST Expands Dublin Facility to Boost Injectable Therapy Capacity
West Pharmaceutical Services (WST) has expanded its Dublin facility with a new 165,000 square foot building to meet the rising global demand for high-volume injectable therapies, especially for chronic diseases like diabetes and obesity. This expansion enhances WST's contract manufacturing capabilities under its West Vantage platform, offering end-to-end development support and strengthening its position in the injectable drug delivery market. Following this news and strong Q4 2025 results, the company expects sustained growth and improved long-term value.
West Pharmaceutical Services opens expanded Dublin facility for injectable therapies
West Pharmaceutical Services announced the opening of an expanded 165,000-square-foot facility for contract services in Dublin, Ireland, creating 330 new jobs. This expansion enhances West's capabilities in high-volume injectable therapies, including GLP-1 treatments for diabetes and obesity, and increases global capacity for integrated drug delivery solutions. The company's comprehensive contract services, West Vantage, aim to accelerate market entry for pharmaceutical and biotechnology partners by providing scalable solutions for life-enhancing therapies.
Rockland Trust Co. Has $1.70 Million Position in West Pharmaceutical Services, Inc. $WST
Rockland Trust Co. significantly reduced its stake in West Pharmaceutical Services by 92.6% in the fourth quarter, selling 76,903 shares but still holding 6,163 shares valued at $1.696 million. Despite this, institutional ownership remains high at 93.9%. West Pharmaceutical recently beat earnings estimates, announced a $1 billion share buyback, and analysts maintain a "Buy" rating with a consensus target price of $314.56.
330 Jobs Created As West Pharmaceuticals Expands Its Dublin Operations
West Pharmaceuticals has expanded its Irish operations by opening a 165,000 square foot extension to its manufacturing site in Damastown, Dublin, creating 330 new jobs. This expansion significantly increases the company's footprint in Ireland, now employing over 1,400 people across its Dublin and Waterford sites, and will focus on producing high-specification components for injectable medicines, particularly amidst growing demand for therapies like GLP-1 treatments. The move reinforces Ireland's position as a key hub for global pharmaceutical production and strengthens the healthcare supply chain, with IDA Ireland applauding the investment's positive impact on the local economy and the country's life sciences sector.
West Pharmaceutical Services Inc. stock rises Tuesday, still underperforms market
West Pharmaceutical Services Inc. (WST) stock increased by 2.24% on Tuesday, closing at $250.64. Despite this gain, the stock underperformed the broader market, as the S&P 500 Index and Dow Jones Industrial Average saw larger increases of 2.91% and 2.49% respectively. This marks the second consecutive day of gains for West Pharmaceutical Services Inc.
West Expands Dublin Facility to Support High-Volume Injectable Therapies, Including Diabetes and Obesity
West Pharmaceutical Services has opened a new 165,000 square foot facility in Dublin, significantly expanding its contract services to meet the growing global demand for high-volume injectable treatments, particularly for diabetes and obesity. This expansion enhances West's capabilities in drug handling, device assembly, and packaging, reinforcing its role in accelerating time to market for life-enhancing therapies. The new facility forms part of West Vantage™, the company's comprehensive contract services business, offering a single-source solution from product conceptualization to regulatory support.
In a $3.889B boat market, Twin Vee picks Nautical Ventures
Twin Vee PowerCats Co. (Nasdaq:VEEE) has named Nautical Ventures Group as its exclusive authorized dealer in Broward County, Florida, effective March 31, 2026. This partnership is strategically important given Broward County's $3.889 billion marine market in 2022. The agreement includes initial inventory deliveries in the coming weeks and a collaboration to develop two custom adventure boat models tailored for South Florida.
Here's What to Expect From West Pharmaceutical's Next Earnings Report
West Pharmaceutical Services, Inc. (WST) is projected to report Q1 2026 EPS of $1.68, a 15.9% increase year-over-year, and has consistently beaten Wall Street estimates in the past four quarters. Analysts are highly bullish on WST, with a "Strong Buy" rating and an average price target of $319.07, indicating a 30.2% upside. Despite underperforming the S&P 500, the stock has shown resilience and grew 2.8% after better-than-expected Q4 2025 earnings results.
West Pharmaceutical Services, Inc. $WST Shares Sold by Bright Rock Capital Management LLC
Bright Rock Capital Management LLC significantly reduced its stake in West Pharmaceutical Services (NYSE: WST) by 87.5% in the fourth quarter, selling 35,000 shares but still owning 5,000 shares valued at $1.376 million. Despite this, West Pharmaceutical Services reported strong Q4 earnings, beating analyst estimates with $2.04 EPS and $805 million in revenue, leading to a share repurchase plan of $1.0 billion and a quarterly dividend declaration. Other institutional investors have both increased and decreased their positions, with overall institutional ownership at 93.9% and a consensus "Buy" rating from analysts.
West Pharmaceutical creates 330 jobs amid opening of new building
West Pharmaceutical Services has officially opened its expanded manufacturing site in Damastown, Dublin, creating 330 jobs. The facility will enhance the company's capabilities in injectable drug administration, including advanced automation and expanded drug-handling for high-volume therapies like GLP-1 treatments. This expansion strengthens West's role in supplying essential medicines and supports the local community with highly-skilled engineering and technical roles.
Wealth Enhancement Advisory Services LLC Sells 7,693 Shares of West Pharmaceutical Services, Inc. $WST
Wealth Enhancement Advisory Services LLC reduced its holdings in West Pharmaceutical Services, Inc. by 26.4%, selling 7,693 shares in the fourth quarter. Despite this, other institutional investors have increased their stakes, and the company has received a consensus "Buy" rating from analysts with an average target price of $314.56. West Pharmaceutical Services also reported strong quarterly earnings, beat revenue expectations, and authorized a $1.0 billion share repurchase program.
WST SEC Filings - West Pharm Svcs 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to West Pharmaceutical Services (WST) SEC filings, including annual 10-K reports, quarterly 10-Q reports, and 8-K material event forms, along with AI-powered summaries and insider trading details. Recent filings highlight executive equity transactions involving restricted stock units and performance stock units, and the company's 2025 10-K report detailed global operations, key risks, and financial performance. The platform aims to offer investors timely regulatory information and analysis.
DAVENPORT & Co LLC Has $2.62 Million Position in West Pharmaceutical Services, Inc. $WST
DAVENPORT & Co LLC has significantly increased its holdings in West Pharmaceutical Services, Inc. (NYSE:WST), boosting its stake by 559.8% to 9,521 shares valued at $2.62 million. Other institutional investors have also adjusted their positions in the medical instruments supplier, which has an average analyst rating of "Buy" and recently reported strong quarterly earnings and declared a dividend. The company also announced a $1 billion stock buyback program, indicating management's belief that shares are undervalued.
DAVENPORT & Co LLC Has $2.62 Million Position in West Pharmaceutical Services, Inc. $WST
DAVENPORT & Co LLC significantly increased its stake in West Pharmaceutical Services, Inc. (WST) by 559.8% in Q4, holding 9,521 shares valued at approximately $2.62 million. West Pharmaceutical Services outperformed quarterly expectations with $2.04 EPS and $805 million in revenue, provided strong FY2026 guidance, and has a consensus "Buy" rating from analysts with an average target price of $314.56. The company also announced a $1.0 billion share buyback authorization and a quarterly dividend of $0.22, demonstrating a commitment to shareholder returns.
Upcoming drug delivery talk sees West Pharmaceutical Services stock fall 1.92% amid weak technical signals
West Pharmaceutical Services (WST) stock fell 1.92% amidst weak technical signals, coinciding with the upcoming presentation by Katie Falcone at the SAE Media Group PFS & Injectable Drug Devices East Coast Conference. Technical indicators suggest persistent selling pressure and a low probability of an upside move, with WST consolidating between $240.50 and $245.90. The stock is currently trading below its short and medium-term moving averages, pointing to potential further downside or sideways movement.
Is West Pharmaceutical Services (WST) Pricing Justified After Mixed Returns And Rich P/E Multiple
West Pharmaceutical Services (WST) has shown mixed returns recently, with a 10.2% decline year to date but a 10.1% gain over one year. Valuation checks by Simply Wall St score the company low, indicating potential overvaluation. Both Discounted Cash Flow (DCF) and Price-to-Earnings (P/E) ratio analyses suggest WST is significantly overvalued compared to its intrinsic value and industry averages.
Nordea Investment Management AB Increases Position in West Pharmaceutical Services, Inc. $WST
Nordea Investment Management AB increased its stake in West Pharmaceutical Services ($WST) by 42.7% in the fourth quarter, now owning 14,950 shares valued at $4.122 million. West Pharmaceutical Services beat Q4 earnings and revenue estimates, provided strong FY 2026 guidance, and approved a $1.0 billion share buyback program. The company also announced a quarterly dividend of $0.22, with analysts maintaining a "Buy" consensus rating and a target price of $314.56.
Vanguard (NYSE: WST) reports 0% stake after January 12, 2026 realignment
The Vanguard Group has filed an amendment to its Schedule 13G/A, reporting 0% beneficial ownership of West Pharmaceutical Services Inc (WST) common stock. This change follows an internal realignment on January 12, 2026, where certain Vanguard subsidiaries will now report their holdings separately. This disaggregation means Vanguard Group no longer beneficially owns these shares, but individual Vanguard subsidiaries may continue to hold WST stock.
West Pharmaceutical Services Inc. stock underperforms Friday when compared to competitors
West Pharmaceutical Services Inc. (WST) saw its stock price fall by 1.92% to $243.35 on Friday, underperforming the broader market. This decline occurred during a generally negative trading session where the S&P 500 Index dropped 1.67% and the Dow Jones Industrial Average fell 1.73%. The stock's loss ended a four-day streak of gains.
Riverbridge Partners LLC Has $87.66 Million Stake in West Pharmaceutical Services, Inc. $WST
Riverbridge Partners LLC reduced its stake in West Pharmaceutical Services by 12.1% in the fourth quarter, now holding 318,613 shares valued at approximately $87.66 million. Despite this reduction, West Pharmaceutical Services reported strong quarterly earnings, beating expectations with $2.04 EPS and $805 million in revenue, and announced a $1.0 billion share buyback program and a $0.22 quarterly dividend. Analysts maintain a generally positive outlook, with an average "Buy" rating and a price target of $314.56.
SG Americas Securities LLC Boosts Stake in West Pharmaceutical Services, Inc. $WST
SG Americas Securities LLC significantly increased its holdings in West Pharmaceutical Services, Inc. by 278.4% in the fourth quarter of 2025, now owning over 100,000 shares valued at approximately $27.76 million. The increase comes as West Pharmaceutical Services reported stronger-than-expected Q4 earnings, beat revenue estimates, provided positive FY2026 guidance, and authorized a $1 billion share buyback program. Analysts currently rate the stock with an average "Buy" and a consensus target price of $314.56, suggesting potential upside from its recent trading price around $248.
Dropper Market Set to Boom Rapidly by 2033 | AptarGroup Inc. • Berry Global Inc. • Silgan Holdings Inc
A new report by Coherent Market Insights forecasts rapid growth for the Dropper Market by 2033, driven by current trends, growth drivers, and technological advancements. The report offers an in-depth analysis of the industry, including competitor analysis, regional market evaluation, and key insights for businesses. Major companies covered include AptarGroup Inc., Berry Global Inc., and Silgan Holdings Inc., with segmentation across pharmaceuticals, cosmetics, food and beverage, and other sectors.
Is West Pharmaceutical Services, Inc. (WST) A Good Stock To Buy Now?
This article summarizes a bullish thesis on West Pharmaceutical Services, Inc. (WST) from MaxDividends’s Substack, highlighting the company's critical role in the injectable drug supply chain, strong competitive moat, and disciplined capital allocation. Despite a modest dividend yield, the investment case focuses on long-term earnings expansion and the company's ability to compound earnings as demand for injectable therapies grows. The article also notes that WST is not among the 40 Most Popular Stocks Among Hedge Funds, suggesting other AI stocks might offer higher, quicker returns.
Is West Pharmaceutical Services, Inc. (WST) A Good Stock To Buy Now?
An article discusses whether West Pharmaceutical Services, Inc. (WST) is a good stock to buy, based on a bullish thesis from MaxDividends. The company supplies critical components for injectable drugs, benefiting from high switching costs and a strong competitive moat. Despite a modest dividend, the investment case focuses on long-term earnings growth due to increasing demand for injectable and biologic therapies.
West Pharmaceutical CEO Plans Exit after 11 Years, Succession Process Underway
West Pharmaceutical Services, Inc. (NYSE: WST) CEO Eric Green announced his retirement after an 11-year tenure, with the transition expected in the second half of 2026. Green will pursue board and advisory roles, having significantly increased sales and shareholder returns during his leadership. The company has initiated a search for his successor.
West Pharmaceutical CEO plans exit after 11 years, succession process underway
NULL
West Pharmaceutical CEO plans exit after 11 years, succession process underway
This article reports that the CEO of West Pharmaceutical is planning to exit the company after 11 years. A succession process is currently underway to find a new leader. Without further content, details about the reasons for the exit or the specific timeline for the succession are unknown.
West Pharmaceutical CEO Plans Exit after 11 Years, Succession Process Underway
Eric Green, CEO of West Pharmaceutical Services, Inc. (NYSE: WST), announced his retirement after an 11-year tenure, with the transition expected in the second half of 2026. The company has initiated a search for his successor, bringing in an executive search firm. During Green's leadership, West Pharmaceutical more than doubled its sales and achieved a total shareholder return of approximately 350%.
West Pharmaceutical CEO Plans Exit after 11 Years, Succession Process Underway
Eric Green, CEO of West Pharmaceutical Services, Inc. (NYSE: WST), will retire after 11 years, with the transition expected in the second half of 2026. The company has initiated a search for his successor. During Green's tenure, sales more than doubled and the company delivered a total shareholder return of approximately 350%.
Revvity Inc. stock faces pressure amid life sciences sector slowdown as Q4 earnings loom
Revvity Inc. is facing pressure due to a slowdown in the life sciences sector, marked by reduced research funding and biopharma spending cuts, which led to flat Q4 revenue and organic declines. US investors should monitor the upcoming Q4 results for insights into NIH funding impacts, biopharma R&D recovery, and the integration of acquisitions like BioLegend, especially given the company's significant US customer base and the resilience of its diagnostics segment. Despite sector headwinds, the company's services business provides stability, while its valuation and strategic acquisitions offer potential upside for growth-seeking investors.
West Pharmaceutical Services to present FluroTec Barrier Film benefits at ChemPharma Summit
West Pharmaceutical Services will attend the ChemPharma International Summit, where expert Lynn Yao will present on the benefits of West FluroTec Barrier Film at Stand B10. The company aims to strengthen industry partnerships and showcase its advancements in pharmaceutical packaging. This participation follows recent recognitions for its packaging and drug delivery technology and its call for industry adaptation to new contamination control standards.
Therapy animals will reach 100,000 patients and care teams in pilot
Pet Partners and the Baxter Foundation (NYSE: BAX) have launched a two-year pilot program to expand therapy animal visits, aiming to reach 100,000 patients and healthcare workers in three key U.S. regions. This initiative seeks to reduce stress and improve resilience by providing resources, training, and volunteer support, building on the proven benefits of human-animal interaction in healthcare settings. The program also includes research to further understand the impact of therapy animals on healthcare professionals and offers engagement opportunities for Baxter employees.
Assenagon Asset Management S.A. Has $69.06 Million Stake in West Pharmaceutical Services, Inc. $WST
Assenagon Asset Management S.A. increased its stake in West Pharmaceutical Services by 32.9% in the fourth quarter, bringing its total holdings to 251,006 shares valued at $69.06 million. Several other institutional investors also adjusted their positions in the medical instruments supplier. West Pharmaceutical Services reported strong quarterly earnings, beating analyst estimates, and announced a quarterly dividend and a $1 billion share buyback program.
West Pharmaceutical Services Inc. stock outperforms competitors on strong trading day
Shares of West Pharmaceutical Services Inc. (WST) rose 1.60% to $245.27 on Tuesday, outperforming the broader market during a tough trading session. Both the S&P 500 Index and Dow Jones Industrial Average experienced declines. This marked the second consecutive day of gains for West Pharmaceutical Services Inc. stock.
Assessing West Pharmaceutical Services (WST) Valuation After Mixed Returns And Premium P/E Multiple
West Pharmaceutical Services (WST) stock is currently priced at $241.40, with mixed short-term and long-term returns. While a narrative fair value suggests it is 29% undervalued at $338.57, driven by expected margin improvements and revenue growth from new initiatives, its P/E ratio of 35.2x compared to an industry average of 21.7x points towards potential valuation risk. Investors are encouraged to consider both the optimistic valuation narrative and the signal from its elevated P/E multiple.
West Pharmaceutical Services, Inc. $WST is Seilern Investment Management Ltd's 7th Largest Position
Seilern Investment Management Ltd reduced its stake in West Pharmaceutical Services (WST) by 14.9%, though WST remains its 7th largest holding. West Pharmaceutical exceeded Q4 earnings and revenue expectations, and institutional ownership stands at a high 93.9%. Analysts hold a consensus "Buy" rating for WST with a price target implying significant upside.
West Pharmaceutical Services Inc. stock outperforms competitors on strong trading day
West Pharmaceutical Services Inc. (WST) saw its stock rise by 1.84% to $241.40, outperforming the broader market during a positive trading session. Both the S&P 500 Index and the Dow Jones Industrial Average also experienced gains. Despite this rise, the company's stock remains 25.11% below its 52-week high.
Pharmaceutical Unit Dose Packaging Market Is Going to Boom | AptarGroup Inc. • Omnicell Inc. • Becton
Coherent Market Insights has released a new report, "Pharmaceutical Unit dose Packaging Market," analyzing current trends, growth drivers, challenges, and opportunities from 2026-2033. The report offers insights into market dynamics, regional outlook, and competitor landscape, featuring major companies like AptarGroup Inc., Omnicell Inc., and Becton, Dickinson and Company. Employing both primary and secondary research, it aims to help businesses forecast profitability and make informed strategic decisions.
Leadership Shake-Up And Push For Independent Chair Might Change The Case For Investing In West (WST)
West Pharmaceutical Services is undergoing a leadership transition with CEO Eric M. Green's planned retirement in late 2026, coinciding with a shareholder proposal for an independent board chair. This governance shift is prompting investors to re-evaluate the company's investment narrative, although its 2026 revenue guidance remains reaffirmed. The article suggests that while the changes are significant, they don't immediately alter the core operational risks or catalysts for the drug and biotech supplier, which has a modest growth forecast and a relatively full valuation.
AptarGroup’s Nasal Devices Gain Ground In Respiratory Trials And Leadership Shift
AptarGroup's nasal devices are gaining traction in respiratory trials, highlighted by the use of their Unidose Powder Nasal Spray System in ENA Respiratory's Phase II trial for INNA-051, a non-vaccine approach to preventing viral respiratory infections. This development positions AptarGroup as a key player in advanced nasal drug delivery technologies, aligning with the strategic vision of incoming President Gael Touya. Investors are advised to monitor the expanded use of Aptar's platforms in clinical trials and the strategic execution of its leadership transition.
Swiss Life Asset Management Ltd Acquires 11,930 Shares of Veralto Corporation $VLTO
Swiss Life Asset Management Ltd increased its stake in Veralto Corporation by 18.0%, purchasing an additional 11,930 shares to bring its total holdings to 78,343 shares valued at approximately $8.35 million. Veralto recently beat its Q4 EPS expectations but slightly missed revenue estimates, while analysts currently hold a consensus "Hold" rating with an average price target of $108.22. The company also declared a quarterly dividend of $0.13 per share.
West Pharmaceutical Stock Faces Pressure Amid Pharma Supply Chain Shifts and Earnings Anticipation
West Pharmaceutical Services (WST) stock is under pressure due to headwinds from biosimilar competition, supply chain disruptions, and slowing growth in proprietary products, despite its crucial role in drug delivery systems. Investors are keenly awaiting Q1 2026 earnings, expected to be released on April 25, amid concerns about margin compression and inventory destocking. The company, however, maintains strong fundamentals with a debt-free balance sheet and strategic investments in expansion and innovation.
